Corporate News

INMUNOTEK at the EAACI 2018 congress

July 2018

INMUNOTEK has been present at the annual conference of the EAACI (European Academy of Allergy and Clinical Immunology). The current edition, EAACI 2018, has taken place in Munich. In addition to the commercial exhibition, INMUNOTEK has participated contributing scientifically in the form of oral communications and posters.
More info

INMUNOTEK at the EAACI 2018 congress

June 2018

INMUNOTEK has been present at the annual conference of the EAACI (European Academy of Allergy and Clinical Immunology). The current edition, EAACI 2018, has taken place in Munich. In addition to the commercial exhibition, INMUNOTEK has participated contributing scientifically in the form of oral communications and posters.
More info

US patent granted

April 2018

The US Patent Office has granted to INMUNOTEK the patent US9901633B2. This refers to new glycoconjugates performed with non-oxidized mannan derived from S. cerevisiae that can be used for designing novel vaccines targeting dendritic cells. This approach is being used for the development of allergy vaccines with improved immunomodulatory properties.
More info

INMUNOTEK has made the 2018 Inc.5000 list

March 2018

Inc. magazine revealed the 2018 Inc. 5000 list of fastest-growing private companies in Europe.  With an accumulated growth of more than 80%, INMUNOTEK has made into this ranking.
More info

Japan patent granted

February 2018

The Japan Patent Office has granted to INMUNOTEK the patent JP6285012B2 . This refers to new glycoconjugates performed with non-oxidized mannan derived from S. cerevisiae that can be used for designing novel vaccines targeting dendritic cells. This approach is being used for the development of allergy vaccines with improved immunomodulatory properties.
More info